Now Reading: Aptus Pharma to raise Rs 45 crore via preferential issue
-
01
Aptus Pharma to raise Rs 45 crore via preferential issue
Aptus Pharma plans to raise Rs 45 crore through a preferential issue of shares, subject to shareholder approval at its Annual General Meeting on September 14, 2026. The proceeds will be used…
Aptus Pharma plans to raise Rs 45 crore through a preferential issue of shares, subject to shareholder approval at its Annual General Meeting on September 14, 2026. The proceeds will be used over 36 months for manufacturing and global expansion.
The company aims to meet about 20 per cent of its product needs through in-house manufacturing, gaining control over quality and supply chain. It also plans to strengthen its domestic sales network across West, Central, East and South India, targeting a Pan-India presence.
Internationally, Aptus Pharma will explore opportunities in Africa, the Middle East and Latin America through product registrations and export partnerships, based on commercial viability and regulatory approvals.
Indian Opinion Analysis
The preferential-issue route lets Aptus Pharma raise capital without a public offering, targeting existing investors. At a time when the Rs 600-crore Indian pharmaceutical market sees rising demand for generic drugs in emerging economies, the company's push into Africa, the Middle East and Latin America mirrors a broader industry trend of Indian drugmakers expanding overseas. The shareholder vote on September 14 will determine if the plan proceeds. If approved, the 36-month utilisation period means investment milestones may begin showing in earnings by late 2026.
Source: businesstoday.in
This story was synthesised by AI from the source linked above.
